Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity

BACKGROUND: In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tao, Qiao, Chunxia, Lv, Ming, Tang, Luqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530185/
https://www.ncbi.nlm.nih.gov/pubmed/31118070
http://dx.doi.org/10.1186/s12896-019-0524-8
_version_ 1783420575805341696
author Yu, Tao
Qiao, Chunxia
Lv, Ming
Tang, Luqun
author_facet Yu, Tao
Qiao, Chunxia
Lv, Ming
Tang, Luqun
author_sort Yu, Tao
collection PubMed
description BACKGROUND: In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple myeloma. RESULTS: Here we obtained a humanized anti-CD38 antibody, SG003, using SDR-grafting method. SG003 possessed stronger antigen binding activity than Daratumumab, and its epitope was far from that of Daratumumab, an anti-CD38 antibody currently in the clinical trials for multiple myeloma; besides, SG003 showed enhanced antibody-dependent cell-mediated cytotoxicity function and in vivo inhibitory efficacy of tumor growth in xenograft mice model. CONCLUSION: SG003 seemed to be a good option to improve the curative effect of CD38-related cancers.
format Online
Article
Text
id pubmed-6530185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65301852019-05-28 Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity Yu, Tao Qiao, Chunxia Lv, Ming Tang, Luqun BMC Biotechnol Research Article BACKGROUND: In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple myeloma. RESULTS: Here we obtained a humanized anti-CD38 antibody, SG003, using SDR-grafting method. SG003 possessed stronger antigen binding activity than Daratumumab, and its epitope was far from that of Daratumumab, an anti-CD38 antibody currently in the clinical trials for multiple myeloma; besides, SG003 showed enhanced antibody-dependent cell-mediated cytotoxicity function and in vivo inhibitory efficacy of tumor growth in xenograft mice model. CONCLUSION: SG003 seemed to be a good option to improve the curative effect of CD38-related cancers. BioMed Central 2019-05-22 /pmc/articles/PMC6530185/ /pubmed/31118070 http://dx.doi.org/10.1186/s12896-019-0524-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yu, Tao
Qiao, Chunxia
Lv, Ming
Tang, Luqun
Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title_full Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title_fullStr Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title_full_unstemmed Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title_short Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
title_sort novel anti-cd38 humanized mab sg003 possessed enhanced cytotoxicity in lymphoma than daratumumab via antibody-dependent cell-mediated cytotoxicity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530185/
https://www.ncbi.nlm.nih.gov/pubmed/31118070
http://dx.doi.org/10.1186/s12896-019-0524-8
work_keys_str_mv AT yutao novelanticd38humanizedmabsg003possessedenhancedcytotoxicityinlymphomathandaratumumabviaantibodydependentcellmediatedcytotoxicity
AT qiaochunxia novelanticd38humanizedmabsg003possessedenhancedcytotoxicityinlymphomathandaratumumabviaantibodydependentcellmediatedcytotoxicity
AT lvming novelanticd38humanizedmabsg003possessedenhancedcytotoxicityinlymphomathandaratumumabviaantibodydependentcellmediatedcytotoxicity
AT tangluqun novelanticd38humanizedmabsg003possessedenhancedcytotoxicityinlymphomathandaratumumabviaantibodydependentcellmediatedcytotoxicity

Ejemplares similares